Lv3
218 积分 2026-05-09 加入
2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns
2天前
已完结
Management of hot flashes in women with breast cancer receiving ovarian function suppression
2天前
已完结
Efficacy and Safety of Anlotinib‐Based Regimens in Metastatic Breast Cancer: A Multicenter Real‐World Study
2天前
已完结
Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis
2天前
已关闭
A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2天前
已完结
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort
2天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
2天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2天前
已完结
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study
2天前
已完结
Safety and Efficacy of Atezolizumab in Combination With nab-Paclitaxel in Patients With PD-L1 Positive Metastatic or Locally Advanced Triple-Negative Breast Cancer: A UK-Wide Cancer Centre Experience
2天前
已完结
皖公网安备34019202002308
